GenSight Pulls $65M IPO, 2nd Biotech To Do So This Week
GenSight Biologics SA withdrew its plans for a $65.1 million initial public offering on Thursday, citing difficult market conditions, a day after fellow biotechnology company Bavarian Nordic AS pulled its planned...To view the full article, register now.
Already a subscriber? Click here to view full article